Drug updated on 3/28/2024
| Dosage Form | Tablet (oral: 75 mg) |
| Drug Class | Calcitonin gene-related peptide receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated foor the acute treatment of migraine with or without aura in adults.
- Indicated for the treatment of episodic migraine in adults.
Summary
- Rimegepant (Nurtec ODT) is indicated for the acute treatment of migraine with or without aura in adults, as well as for the episodic treatment of migraines.
- A total of 11 systematic reviews and meta-analyses were reviewed to gather information about this drug's safety and effectiveness.
- In terms of safety, rimegepant has a favorable profile compared to other drugs such as ubrogepant and lasmiditan; it shows no significant difference in adverse events when compared to placebo.
- The occurrence of side effects like nausea, dizziness, diarrhea, and muscle strain was found more frequently among patients who had aura symptoms at baseline during their migraine episodes.
- Compared to traditional triptans used for treating migraines, rimegepant presents lower risks making it a safer option especially for patients with cardiovascular risks where triptans are contraindicated.
- Effectiveness-wise, rimegepant provides relief from migraine symptoms better than placebo does; however its efficacy slightly trails behind that noted with lasmiditan 200 mg dosage specifically regarding two-hour pain freedom post-dose administration.
- Ubrogepant showed superior efficacy over placebo but appeared less effective than lasmiditan on certain endpoints like pain freedom at two hours post-dose administration despite having better tolerability profile overall according to one study.
- Body Mass Index (BMI) impacts liver function values and dosage tolerability which suggests subgroup considerations might be necessary while prescribing these medications.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Nurtec ODT (rimegepant) Prescribing Information. | 2023 | Biohaven Pharmaceuticals Inc., New Haven, CT |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| VA/DoD clinical practice guidelines: the primary care management of headache. | 2020 | U.S Department of Veteran Affairs |